Status:
TERMINATED
Neuromuscular Electrical Stimulation in ICU Patients
Lead Sponsor:
Federal University of Rio Grande do Sul
Conditions:
Intensive Care Unit Acquired Weakness
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim of the present study is to evaluate the effects of neuromuscular electrical stimulation (NMES) combined with conventional physiotherapy (Experimental Group), compared to conventional physiothe...
Detailed Description
The aim of the present study is to evaluate the effects of neuromuscular electrical stimulation (NMES) combined with conventional physiotherapy (Experimental Group), compared to conventional physiothe...
Eligibility Criteria
Inclusion
- Patients with any clinical condition hospitalized in the ICU, which are monitored by the Physiotherapy Service:
- Cerebrovascular diseases
- Other bacterial diseases
- Circulatory and respiratory diseases
- Digestive and abdominal diseases
- Liver diseases
- Time between the patient's ICU entry and the onset of the NMES intervention less than one week.
- Patients may be in mechanical ventilation, non-invasive ventilation, oxygen therapy or oxygen ambient ventilation (no ventilatory add). Patients re-admitted to the ICU within the same hospitalization period (i.e., did not leave the hospital) may also be included, as well as patients with previous tracheostomy.
Exclusion
- Previously diagnosed neuromuscular diseases:
- ALS
- Guillain Barre
- Chronic stroke
- TRM
- End-stage malignant disease
- Lower limbs' amputation
- Body mass index above 40 kg/m2
- Cachexia (defined as the presence of chronic disease and weight loss ≥ 5% in a period shorter than 12 months or BMI \< 20 kg/m2, associated with at least three of the following criteria: (1) decreased muscle strength; (2) fatigue; (3) anorexia; (4) reduction of fat free mass index; and (5) biochemical abnormalities such as inflammation, anemia or reduction of serum albumin concentration).
- Lesions on the skin at the electrode placement and/or dynamometer support points
- Post-operative transplantation
- Patients using a neuromuscular blocker
- Hemodynamic instability (nora \> 10; ABCDE criteria)
- Height \< 1.50m
- Rhabdomyolysis
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 6 2024
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT04332263
Start Date
March 1 2022
End Date
June 6 2024
Last Update
June 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universidade Federal do Rio Grande do Sul
Porto Alegre, Rio Grande do Sul, Brazil, 90690-200